SCHEMBL16993176

SCHEMBL16993176

COc1cc(OC)c(Cl)c(-c2cc3cnc(S(C)(=O)=O)nc3n(CCN(C(=O)C(F)(F)F)C3CN(C(=O)OC(C)(C)C)C3)c2=O)c1Cl

nearest known ligand 0.51

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 20/20 0.51
FGFR2 P21802 11/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16993194 0.91 FGFR1 (0.50) FGFR1FGFR2
SCHEMBL16993401 0.89 FGFR1 (0.64) FGFR1FGFR2
SCHEMBL17910139 0.89 FGFR1 (0.51) FGFR1FGFR2
SCHEMBL16993123 0.84 FGFR1 (0.61) FGFR1FGFR2
SCHEMBL19499687 0.84 FGFR1 (0.49) FGFR1FGFR2
SCHEMBL17910146 0.83 FGFR1 (0.63) FGFR1FGFR2
SCHEMBL19499704 0.83 FGFR1 (0.59) FGFR1FGFR2
SCHEMBL18497689 0.82 FGFR1 (0.62) FGFR1FGFR2
SCHEMBL19499693 0.81 FGFR1 (0.47) FGFR1FGFR2
SCHEMBL16993021 0.80 FGFR1 (0.61) FGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162882-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMAC, INC. (US) 2024-12-10 US disclosed
US-20240092777-A1 Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2024-03-21 US disclosed
US-20210292323-A1 Quinolone Derivatives as Fibroblast Growth Factor Inhibitors PRINCIPIA BIOPHARMA INC. (US) 2021-09-23 US disclosed
US-11078199-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2021-08-03 US disclosed
US-20190233418-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC. 2019-08-01 US disclosed
US-10294223-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2019-05-21 US disclosed
EP-3102577-B1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC (US) 2018-07-18 EP disclosed
US-20180065960-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC. 2018-03-08 US disclosed
US-9815834-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2017-11-14 US disclosed
US-9567334-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors PRINCIPIA BIOPHARMA, INC. (US) 2017-02-14 US disclosed
EP-3102577-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS Principia Biopharma Inc. (US) 2016-12-14 EP disclosed
US-20160229849-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC. 2016-08-11 US disclosed
US-20160200725-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA INC. 2016-07-14 US disclosed
WO-2015120049-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS PRINCIPIA BIOPHARMA, INC. (US) 2015-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162882-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885
US-11078199-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885
US-20160200725-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885
US-20210292323-A1 Quinolone Derivatives as Fibroblast Growth Factor Inhibitors FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885
US-20190233418-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885
US-20240092777-A1 Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885
US-10294223-B2 Quinolone derivatives as fibroblast growth factor receptor inhibitors FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885
US-20160229849-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885
US-20180065960-A1 QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS FGFR1, FGFR3, FGFR2 FGFR1 1/4885FGFR2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.